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Enhanced response rate to pegylated
liposomal doxorubicin in high grade serous
ovarian carcinomas harbouring BRCA1 and
BRCA2 aberrations
Robert L. Hollis1, Alison M. Meynert2, Michael Churchman1, Tzyvia Rye1, Melanie Mackean3, Fiona Nussey3,
Mark J. Arends4, Andrew H. Sims1, Colin A. Semple2, C. Simon Herrington1,4,5 and Charlie Gourley1,3*
Abstract
Background: Approximately 10–15% of ovarian carcinomas (OC) are attributed to inherited susceptibility, the
majority of which are due to mutations in BRCA1 or BRCA2 (BRCA1/2). These patients display superior clinical
outcome, including enhanced sensitivity to platinum-based chemotherapy. Here, we seek to investigate whether
BRCA1/2 status influences the response rate to single-agent pegylated liposomal doxorubicin (PLD) in high grade
serous (HGS) OC.
Methods: One hundred and forty-eight patients treated with single-agent PLD were identified retrospectively from
the Edinburgh Ovarian Cancer Database. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) archival
tumour material and sequenced using the Ion Ampliseq BRCA1 and BRCA2 panel. A minimum variant allele
frequency threshold was applied to correct for sequencing artefacts associated with formalin fixation.
Results: A superior response rate to PLD was observed in patients with HGS OC who harboured variants likely to affect
BRCA1 or BRCA2 function compared to the BRCA1/2 wild-type population (36%, 9 of 25 patients versus 12.1%, 7 of 58
patients; p = 0.016). An enhanced response rate was also seen in patients harbouring only the BRCA1 SNP rs1799950,
predicted to be detrimental to BRCA1 function (50%, 3 of 6 patients versus 12.1%, 7 of 58 patients; p = 0.044).
Conclusions: These data demonstrate that HGS OC patients with BRCA1/2 variants predicted damaging to protein
function experience superior sensitivity to PLD, consistent with impaired DNA repair. Further characterisation of
rs1799950 is now warranted in relation to chemosensitivity and susceptibility to developing ovarian carcinoma.
Keywords: Ovarian cancer, BRCA1, BRCA2, PLDH
Background
Ovarian cancer represents a substantial cause of mortality
worldwide, with over 21,000 cases diagnosed, accounting
for over 14,000 deaths, per year in the United States alone
[1]. The majority of cases are ovarian carcinomas (OCs),
approximately 10–15% of which arise in patients with
inherited genetic susceptibility to disease [2, 3]. It is now
recognised that the histologically-defined subgroups of
OC represent distinct disease entities both molecularly
and clinically, with high grade serous (HGS) OC account-
ing for the majority of cases (around 70%) [4].
Germline mutations in the DNA repair genes BRCA1
and BRCA2 (BRCA1/2) are responsible for the majority of
hereditary OC, and around 15–20% harbour germline or
somatic BRCA1/2 defects [5, 6]. Mutational inactivation
of BRCA1/2 renders tumours deficient in homologous
recombination DNA damage repair (HRR) [7, 8]. BRCA1/
2-associated OC patients experience superior clinical out-
come, despite their propensity for developing visceral
metastases and a tendency to present with HGS histology
[9–13]. These tumours display superior response rates to
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multiple lines of platinum-based chemotherapy, as well as
superior sensitivity to PARP inhibitors, consistent with
HRR-deficiency and dependence upon error-prone non-
homologous end joining (NHEJ) to repair therapy-induced
DNA damage [9, 14].
Pegylated liposomal doxorubicin (PLD) is a doxorubicin
formulation, liposome-encapsulated and pegylated to in-
crease drug half-life and reduce cardiotoxicity [15, 16].
PLD is often used in OC treatment in the advanced-stage,
relapsed disease setting, with reported response rates of
around 15% when used as a single agent [17, 18]. One
mechanism of action of PLD is the induction of single-
stranded and double-stranded DNA breaks through
both free radical formation and direct intercalation
into DNA, interfering with topoisomerase II-mediated
repair [19].
A phase II trial comparing the PARP inhibitor olaparib at
two doses versus PLD in a population of BRCA1/2-mutant
patients with recurrent OC showed a greater than expected
objective response rate to PLD [20]. Because BRCA1/2
status is known to influence the response rate of pa-
tients to platinum-based chemotherapy, and induction of
DNA damage is a common mechanism of action between
PLD and platinum, we postulated that BRCA1/2 status
may also influence the response rates to PLD.
Three previous studies have attempted to address this
hypothesis, but these investigations have suffered several
methodological limitations [21–23]. All three studies in-
clude a number of untested “presumed BRCA1/2 nega-
tive” OC patients in their wild-type comparator cohorts
[21, 23]. Two studies included a significant number of pa-
tients treated with PLD in combination with other agents,
most commonly platinum, which account for around half
of the PLD-treated population in each study [21, 22]. One
study limited BRCA1/2 sequencing to regions of known
founder mutations [22], and all three studies compared
PLD response in a histologically heterogeneous population.
Furthermore, these studies have limited sequencing to
germline material, despite the substantial number of OC
known to display somatic mutational inactivation of
BRCA1/2 [24, 25]. Given the known differential chemosen-
sitivity of histological subtypes of OC [4], the clear poten-
tial for previous analyses to be confounded by superior
response rate to co-administered platinum in BRCA1/2-as-
sociated OC [9], the limited predictive power of family his-
tory in predicting germline BRCA status in the presumed
negative populations [26], and the known phenotypic over-
lap between germline and somatic BRCA1/2-inactivated
OC [24, 27], there is a clear need for comparison of re-
sponse rate to PLD monotherapy to tumour BRCA1/2 sta-
tus in a histologically uniform OC cohort.
Here we present next generation sequencing (NGS) of
tumour DNA from a cohort of OC patients treated with
PLD monotherapy from a single centre in order to better
interrogate the interaction between BRCA1/2 status and
response to PLD.
Methods
Cohort identification and pathology review
We retrospectively identified all patients treated with PLD
monotherapy between 2001 and 2014 from the Edinburgh
Ovarian Cancer Database (Fig. 1). 148 OC patients were
identified. Of these, tumour material was available for
translational research use in 119 cases. 10 μm sections
were taken from archival tissue blocks alongside a 5 μm
section to be stained with haemotoxylin and eosin (H&E).
Ethical approval for the use of tumour material was
obtained from South East Scotland Human Annotated
Bioresource (East of Scotland Research Ethics Service
Reference 10/S1402/33).
Tumour area identification and pathology review was
conducted by an expert gynaecological pathologist using
the H&E stained slide. Where histological subtype of OC
was unclear from H&E alone, a combination of patient
pathology reports and additional 5 μm sections immuno-
histochemically stained for WT1 and P53 proteins were
used to determine OC histotype.
DNA extraction
H&E stained slides were used to guide macrodissection
of four 10 μm FFPE tissue sections per specimen. DNA
extraction was performed using the QIAamp DNA FFPE
Tissue Kit and Deparaffinization Solution according to
the manufacturer’s instructions.
NGS sequencing of BRCA1 and BRCA2 in FFPE-derived
tumour DNA
Sequencing of the BRCA1 and BRCA2 coding regions
was performed using the Ion Ampliseq BRCA1 and
BRCA2 panel on the Ion Torrent sequencing platform.
111 patients were successfully sequenced for BRCA1 and
BRCA2. BAM files were generated using Torrent Suite
v4.6, and variants called using the Torrent Variant Caller
v4.6.0.7. The minimum per-sample mean depth of cover-
age achieved was 916X; the median per-sample mean
depth achieved was 4728X. The median uniformity of
sequencing depth across targets was 90.5%. Called vari-
ants were functionally annotated using the Ensembl
Variant Effect Predictor Version 75.
Sequencing of FFPE-derived DNA presents the chal-
lenges of both fragmentation and spontaneous deamin-
ation of DNA associated with formalin fixation [28, 29].
Consistent with these fixation artefacts, we observed a bias
in the mutation spectrum of bi-allelic single nucleotide
variants (SNVs) in our study compared to those reported
in OC samples in the TCGA dataset, which utilised fresh
frozen material (Fig. 2a) [25]. Consistent with previous
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reports, the strongest bias was in cytosine to thymine
SNVs, likely as a result of cytosine deamination [29, 30].
To compensate for these artefacts, we applied mini-
mum allele frequency (AF) thresholding to the set of
variants. Comparing the proportion of previously docu-
mented (more likely true) variants retained to the pro-
portion of novel (more likely false) variants, we found
that for minimum AF > 10% more previously docu-
mented variants were lost than novel variants retained
(Fig. 2b). We also compared the mutation spectrum of
all retained bi-allelic SNVs at each AF threshold to the
mutation spectrum from the fresh frozen TCGA sam-
ples, showing that the majority of the bias was removed
at AF ≥ 10% (Table 1 and Additional file 1: Figure S1).
Together, these analyses demonstrated that a 10% AF
threshold removed a large proportion of likely erroneous
variants, while conserving the majority of likely true vari-
ants and minimising the difference in mutation spectrum
compared to the TCGA data. Accordingly, variants de-
tected at AF < 10% were discarded prior to analysis.
Classification of functionally relevant BRCA1 and BRCA2
variants
Frameshift and nonsense variants in BRCA1 and BRCA2
were classified as likely damaging to protein function, as
were previously reported missense mutations with known
pathogenicity. Splice site variants with reported pathogen-
icity were also classified as likely to be damaging. Missense
mutations predicted as unlikely to affect protein function
by both Sorting Intolerant From Tolerant (SIFT) and
PolyPhen scores were discarded as non-functional vari-
ants, while those predicted likely deleterious by both were
Fig. 1 Flow diagram of HGS OC patients evaluable for PLD response
Fig. 2 a Comparison of bi-allelic SNV spectra between DNA extracted from FFPE and fresh frozen material in the TCGA data. b Proportions of
previously documented variants retained (DVR) and novel variants removed (NVR) at various minimum allele frequency (AF) thresholds
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classified as likely to be damaging [31, 32]. Missense mu-
tations with conflicting SIFT and PolyPhen predictions
were discarded as variants of unknown significance.
Three insertion/deletion (indel) variants called at high
frequency across the cohort were identified as suspected
recurrent sequencing errors around homopolymer re-
gions. Sanger sequencing of these regions in the respective
tumours confirmed these as sequencing errors, consistent
with previous reports of false-positive indel calling around
problematic genomic regions on Ion Torrent NGS plat-
forms (Additional file 2: Table S1) [33].
PLD response data
Patient response data were obtained retrospectively from
the Edinburgh Ovarian Cancer Database. Responders
were defined as patients who showed partial or complete
CA125 tumour marker response or radiological response
(either WHO or RECIST criteria as some patients pre-
dated RECIST reporting) from the PLD chemotherapy
package. Patients who experienced stable disease, disease
progression, or succumbed to disease on therapy were
classified as non-responders. Patients for whom both
CA125 data and scans were not available, or who re-
ceived fewer than two cycles of PLD, were considered
unevaluable for PLD response (Fig. 1).
Results
BRCA1 and BRCA2 mutation frequency
Among the 111 successfully sequenced PLD-treated pa-
tients, 46 variants likely to affect protein function were de-
tected, comprising 26 BRCA1 variants and 20 BRCA2
variants. Of the BRCA1 variants, 12 were frameshift-
inducing indels and 14 were missense variants, including
11 instances of the missense-causing SNP rs1799950
conferring a Gln356Arg amino-acid change and predicted
to be detrimental to BRCA1 function by both SIFT and
PolyPhen. Of the BRCA2 variants, 10 were frameshift
indels, 7 were missense variants, 1 was a nonsense muta-
tion and 2 were splice site variants.
Across the study cohort 31.5% (35 of 111) of patients
harboured at least one variant in BRCA1 or BRCA2 pre-
dicted as likely to affect protein function (BRCA1/2-aber-
rant). Specifically, 20.7% (23 of 111 patients) harboured at
least one variant in BRCA1 alone, 9.9% (11 of 111) dis-
played at least one variant in BRCA2 alone, and 0.9% (1 of
111 patients) harboured variants in both BRCA1 and
BRCA2, consistent with previous reports of the higher
BRCA1 mutation frequency in OC versus BRCA2 [10].
Of the BRCA1/2-aberrant population, 97.1% (34 of 35)
were HGS OC, consistent with previous reports of the as-
sociation between BRCA1/2 mutation and HGS histology.
The remaining case was high grade endometrioid OC.
Patient demographics of BRCA1/2-aberrant and BRCA1/2
wild-type populations
There was no difference in FIGO stage at diagnosis, suc-
cess of primary surgical tumour debulking, platinum
sensitivity at PLD therapy initiation, or in the number of
lines of cytotoxic chemotherapy received prior to PLD
between the BRCA1/2-aberrant and wild-type groups
(Table 2). BRCA1/2-aberrant patients were significantly
younger at diagnosis compared with wild-type (median
55 years vs. 64 years, respectively; Welch Two-Sample t-
test p < 0.001), consistent with previous associations of
BRCA1/2 mutation with younger age at diagnosis [34].
PLD therapy response rate
78.4% (87 of 111) of patients were evaluable for response
to PLD. 19.5% (17 of 87) were classified as responders
by virtue of achieving either a CA125 or radiological re-
sponse. This observed response rate is comparable to
that reported in other studies investigating the use of
single agent PLD in the advanced-stage recurrent disease
setting [17, 18, 35].
Different histological subtypes of OC are known to dis-
play distinct response profiles to chemotherapy [36–38].
The vast majority of patients classified as responders had
disease of HGS histology (94.1%, 16 of 17), giving a re-
sponse rate of 19.3% (16 of 83) in the HGS population.
Table 1 Proportion of total SNVs accounted for by each SNV class at various minimum allele frequency (AF) thresholds and
corresponding sum of squares differences (SSD) in SNV mutation spectra between FFPE and fresh frozen TCGA data
Minimum AF threshold Proportion of variants in fresh frozen data
SNV no filter 0.05 0.1 0.15
A > C/T > G 0.017 0.026 0.054 0.051 0.061
A > G/T > C 0.100 0.165 0.286 0.372 0.126
A > T/T > A 0.015 0.023 0.009 0.013 0.087
C > A/G > T 0.017 0.026 0.063 0.064 0.186
C > G/G > C 0.012 0.023 0.036 0.051 0.175
C > T/G > A 0.839 0.737 0.554 0.449 0.366
SSD 0.287 0.193 0.102 0.103 0.000
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Given the limited number of non-HGS patients evaluable
for PLD response in this cohort (N = 4), comparison of
differential response rates to PLD between histological
OC groups could not be made.
BRCA1/2 status influences response rate to PLD in HGS OC
We observed a significantly higher response rate to PLD
in the BRCA1/2-aberrant HGS OC population compared
with the wild-type group in this study (Fig. 3) (36.0%, 9
of 25 patients vs. 12.1%, 7 of 58 patients; Fisher’s exact
test p = 0.016). Of the 9 responses in the BRCA1/2-aber-
rant population, two were radiological, 6 were CA125
tumour marker response, and one was both radiological
and CA125 response. Of the 7 responses in the wild-type
population, two were radiological, three were CA125
tumour marker response, and two were both radiological
and CA125 tumour marker response. This BRCA1/2-aber-
rant population comprised both BRCA1/2-mutant patients
and patients who harboured the predicted detrimental
rs1799950 BRCA1 SNP. When considering patients har-
bouring only rs1799950, we observed a significantly super-
ior response rate to PLD versus the wild-type population
(50%, 3 of 6 patients vs. 12.1%, 7 of 58; Fisher’s exact test
p = 0.044), despite the small numbers of patients in this
group (N = 6). There was a similar trend for superior re-
sponse rate to PLD in the BRCA1/2-mutant population
Table 2 Demographic of PLD-treated patients
BRCA1/2-Aberrant OC (n = 35) Wild-Type OC (n = 76) p-value
No. % No. %
Age at diagnosis, years
Median 55 64 <0.001a
Range 39–77 41–82
Histology
HGS 34 97.1 70 92.1
Endometrioid 1 2.9 2 2.6
Clear Cell 0 0 2 2.6
Mucinous 0 0 0 0.429b
LGS 0 0 0
Carcinosarcoma 0 0 2 2.6
FIGO stage at diagnosis
I 1 2.9 1 1.4
II 3 8.6 4 5.6
III 23 65.7 48 66.7 0.470c
IV 8 22.9 19 26.4
NA 0 0 4
Debulking status
<2 cm 14 42.4 23 31.5 0.282e
≥2 cm 19 57.6 50 68.5
NA 2 3
Platinum sensitivity at PLD initiation
Sensitive 5 15.2 9 12.5
Resistant 28 84.8 63 87.5 0.761d
NA 2 4
No. of chemotherapy lines prior to PLD
≤2 25 71.4 61 80.3 0.429e
>2 10 28.6 15 19.7
Evaluable for PLD response
Evaluable 26 74.3 61 80.3 0.644e
Not evaluable 9 15.7 15 19.7
aWelch Two Sample t-test; bFisher’s exact test, HGS versus non-HGS histology; cFisher’s exact test, early (I-II) versus advanced (III-IV) stage at diagnosis; dFisher’s
exact test; eChi-squared test; NA, not available
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following the exclusion of patients whose tumour har-
boured only rs1799950 (31.6%, 6 of 19 patients vs. 12.1%, 7
of 58 patients; Fisher’s exact test p = 0.075).
Discussion
Using NGS technology, we were able to sequence FFPE-
derived DNA for the BRCA1 and BRCA2 genes in 111
PLD-treated patients at high sequencing depth. We ob-
served a strong bias in the SNV spectrum of FFPE-
derived DNA versus that reported by the TCGA study
which utilised fresh frozen patient material, consistent
with formalin fixation-induced artefacts known to occur
in FFPE-derived DNA [29, 30]. We used a minimum al-
lele frequency cut-off threshold for called variants to
correct the mutation spectrum for these fixation arte-
facts. While this approach risks filtering a minority of
true variants, we have demonstrated that it removes the
bulk of fixation-associated artefacts, whilst retaining the
vast majority of likely true positive variants, achieving a
practical equipoise for variant filtering.
We detected 29 and 22 BRCA1 and BRCA2 sequence
variants likely to affect protein function, respectively.
Among these, we identified rs1799950, a BRCA1 SNP pre-
dicted to be deleterious to protein function by PolyPhen
and SIFT prediction tools. This SNP results in a non-
conservative amino acid change in BRCA1 protein: the
charged residue arginine is incorporated in place of the
uncharged residue glutamine at amino acid 356. A previ-
ous study of high-risk prostate cancer families found that
the minor allele of rs1799950 was associated with an in-
creased risk of developing prostate cancer (OR 2.25, 95%
confidence interval 1.21–4.20), but its relevance to treat-
ment response is unstudied [39]. Furthermore, homozy-
gosity of the minor allele state has previously been
associated with breast cancer risk in a population from
Saudi Arabia [40].
Of the 83 HGS OC patients evaluable for response to
PLD chemotherapy, 19.3% responded to PLD, concurring
with observations in previous studies [17, 18, 35]. Despite
the low number of responders (N = 16), we were able to
show a significantly superior response rate in those har-
bouring BRCA1/2 aberrations predicted damaging to pro-
tein function, when compared to BRCA1/2 wild-type
samples, of approximately 2.5-fold. This is consistent with
the hypothesis that impaired HRR function renders OC
sensitive to non-platinum DNA damaging agents such as
PLD, as well as platinum-based chemotherapy.
A minority of patients harboured the BRCA1 SNP
rs1799950 with no other detected BRCA1/2 defects.
While this group were severely limited by size, we ob-
served a greater than four-fold response rate in this popu-
lation compared to the wild type population. Notably, this
SNP was reported to possess a minor allele frequency of
0.0596 in European populations by the 1000 Genomes
Project, and would therefore be considered a common
variant according to population genetics conventions.
These data suggest that rs1799950 is biologically signifi-
cant in terms of response to cytotoxic chemotherapy, and
further characterisation of this variant is now warranted.
Future studies should seek to evaluate whether rs1799950,
and other common BRCA1 and BRCA2 variants, modu-
late sensitivity to platinum and other DNA damaging
agents in vitro, and address whether such variants convey
inherited susceptibility to malignancy, particularly to OC
and breast carcinoma.
Previous studies have shown that BRCA1-deficient OC
are more likely to display high levels of tumour infiltrat-
ing lymphocytes (TILs) and display an enrichment of
immune response genes [41]. OC with high levels of T
cell infiltration have superior clinical outcome, thought
to be secondary to an improved anti-tumoural immune
response [42, 43]. Recent work has suggested that PLD
may enhance the immune response in BRCA1-deficient
tumours [44], and this may contribute to the improved
benefit from PLD seen in BRCA1/2-aberrant tumours.
The higher response rate in BRCA1/2-aberrant patients
presents an additional argument for prospective BRCA1
and BRCA2 sequencing in all OC patients. Given the low
response rate to PLD in the BRCA1/2 wild-type popula-
tion (12.1% in our cohort), alternative therapies could be
considered for the treatment of patients who have had
Fig. 3 Differential response rate to PLD chemotherapy according to
BRCA1/2 status of sequenced tumour material. * indicates p < 0.05
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germline or somatic BRCA1 and BRCA2 sequencing and
have not displayed functionally relevant genetic changes
in either of these genes. In light of the high response rate
observed in BRCA1/2-aberrant patients, PLD should be
considered as an active treatment option in patients with
known BRCA1/2 mutations.
Moving forward, the question remains as to whether
this observed superior response rate extends to patients
with defects in other components of the HRR pathway.
In particular, detrimental variants in HRR genes known
to be mutationally inactivated in a minority of hereditary
OC – such as BRIP1, PALB2 and CHEK2 – may also
predict response rate to PLD. Furthermore, the impact
on PLD response rate, if any, of epigenetic silencing of
BRCA1 via promoter methylation remains unstudied.
Conclusion
HGS OC patients displaying BRCA1/2 sequence aberra-
tions predicted detrimental to BRCA1 or BRCA2 protein
function display an increased response rate to PLD. Pa-
tients harbouring the common BRCA1 variant rs1799950
may also display a superior response rate to PLD. These
data support the notion that HGS OC patients with
BRCA1/2 mutations are more sensitive to non-platinum
DNA damaging agents compared to their BRCA1/2 wild-
type counterparts. The role of rs1799950 in chemotherapy
sensitivity and predisposition to OC and BC warrants fur-
ther investigation.
Additional files
Additional file 1: Figure S1. Sum of squares differences (SSD) between
our SNV spectrum and the fresh frozen TCGA SNV spectrum at various
allele frequency threshold for variant filtering. (DOCX 53 kb)
Additional file 2: Table S1. Recurrently called variants confirmed as
sequencing errors by Sanger sequencing. (DOCX 11 kb)
Abbreviations
AF: allele frequency; FFPE: formalin-fixed paraffin-embedded;
H&E: haemotoxylin and eosin; HGS: high grade serous; HRR: homologous
recombination DNA repair; Indel: insertion/deletion; NGS: next generation
sequencing; NHEJ: non-homologous end joining; OC: ovarian carcinoma;
PLD: pegylated liposomal doxorubicin; SIFT: Sorting Intolerant From Tolerant;
SNV: single nucleotide variant
Acknowledgements
We extend our thanks to the patients who contributed to this study, and to
the Edinburgh Ovarian Cancer Database from which data were collected for
this research. We would also like to thank the Edinburgh Wellcome Trust
Clinical Research Facility, Western General Hospital, Edinburgh, for their NGS
services, and the Nicola Murray Foundation for their generous support of
the Nicola Murray Centre for Ovarian Cancer Research.
Funding
RH is funded through a Medical Research Council PhD fellowship. MC
received funding from the Nicola Murray Foundation. Funding bodies did
not influence the study design, manuscript preparation, data collection,
analysis or interpretation.
Availability of data and materials
The datasets used and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
The study was conceived by RH, MC and CG and the methodology was
determined by RH, AM, MC, MA, AS, CS, SH and CG. TR, MM and FN contributed
to data collection. All co-authors contributed to the data collection, analysis
and/or interpretation. RH produced the first draft of the manuscript which was
subsequently commented upon and redrafted by all co-authors. All co-authors
agreed to the final draft. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Ethical approval for the use of tumour material was obtained from South
East Scotland Human Annotated Bioresource (East of Scotland Research
Ethics Service Reference 10/S1402/33). This approval was granted without
the requirement for individual patient consent because patient follow-up
data were gathered as part of routine care, and most patients included in




MM has sat on advisory boards for Roche and delivered lectures for Boehringer
Ingelheim. CG has sat on advisory boards for AstraZeneca, Nucana and Clovis
and has delivered lectures for Roche and AstraZeneca. CG has also received
research funding from AstraZeneca, Novartis and Aprea.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Nicola Murray Centre for Ovarian Cancer Research, Edinburgh Cancer
Research UK Centre, MRC IGMM, University of Edinburgh, Western General
Hospital, Crewe Road, Edinburgh EH4 2XU, UK. 2MRC Human Genetics Unit,
MRC IGMM, University of Edinburgh, Edinburgh, UK. 3Edinburgh Cancer
Centre, Western General Hospital, Edinburgh, UK. 4Division of Pathology,
Centre for Comparative Pathology, Edinburgh Cancer Research Centre, MRC
IGMM, University of Edinburgh, Edinburgh, UK. 5Department of Pathology,
Royal Infirmary of Edinburgh, Edinburgh, UK.
Received: 6 February 2017 Accepted: 22 December 2017
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;
65(1):5–29.
2. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1
and BRCA2 mutations account for a large proportion of ovarian carcinoma
cases. Cancer. 2005;104(12):2807–16.
3. Malander S, Rambech E, Kristoffersson U, Halvarsson B, Ridderheim M, Borg
A, et al. The contribution of the hereditary nonpolyposis colorectal cancer
syndrome to the development of ovarian cancer. Gynecol Oncol. 2006;
101(2):238–43.
4. Hollis RL, Gourley C. Genetic and molecular changes in ovarian cancer.
Cancer Biol Med. 2016;13(2):236–47.
5. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations
in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma
identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;
108(44):18032–7.
6. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al.
BRCA mutation frequency and patterns of treatment response in BRCA
mutation-positive women with ovarian cancer: a report from the Australian
ovarian cancer study group. J Clin Oncol. 2012;30(21):2654–63.
7. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-
directed DNA repair. Mol Cell. 1999;4(4):511–8.
8. Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, Ross G, et al.
Mutation in Brca2 stimulates error-prone homology-directed repair of
Hollis et al. BMC Cancer  (2018) 18:16 Page 7 of 8
DNA double-strand breaks occurring between repeated sequences.
EMBO J. 2001;20(17):4704–16.
9. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al.
BRCAness syndrome in ovarian cancer: a case-control study describing the
clinical features and outcome of patients with epithelial ovarian cancer
associated with BRCA1 and BRCA2 mutations. J Clin Oncol Off J Am Soc
Clin Oncol. 2008;26(34):5530–6.
10. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al.
Association between BRCA1 and BRCA2 mutations and survival in women
with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382–90.
11. Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC,
et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women
diagnosed with epithelial ovarian cancer. Clin Cancer Res. 2015;21(3):652–7.
12. Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, et al. Increased
incidence of visceral metastases in scottish patients with BRCA1/2-defective
ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin
Oncol Off J Am Soc Clin Oncol. 2010;28(15):2505–11.
13. Piek JM, Torrenga B, Hermsen B, Verheijen RH, Zweemer RP, Gille JJ, et al.
Histopathological characteristics of BRCA1- and BRCA2-associated
intraperitoneal cancer: a clinic-based study. Familial Cancer. 2003;2(2):73–8.
14. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al.
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous
ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status
in a randomised phase 2 trial. The Lancet Oncology. 2014;15(8):852–61.
15. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al.
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in
patients reaching or exceeding cumulative doses of 500 mg/m2. Ann
Oncol. 2000;11(8):1029–33.
16. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal
doxorubicin. Rationale for use in solid tumours. Drugs. 1997;54(Suppl 4):15–21.
17. Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, et al.
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.
Gynecol Oncol. 2001;81(2):206–12.
18. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, et al.
Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory
epithelial ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(17):
3093–100.
19. Gewirtz DAA. Critical evaluation of the mechanisms of action proposed for
the antitumor effects of the anthracycline antibiotics adriamycin and
daunorubicin. Biochem Pharmacol. 1999;57(7):727–41.
20. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II,
open-label, randomized, multicenter study comparing the efficacy and safety
of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal
doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian
cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(4):372–9.
21. Safra T, Borgato L, Nicoletto MO, Rolnitzky L, Pelles-Avraham S, Geva R, et al.
BRCA mutation status and determinant of outcome in women with
recurrent epithelial ovarian cancer treated with pegylated liposomal
doxorubicin. Mol Cancer Ther. 2011;10(10):2000–7.
22. Safra T, Rogowski O, Muggia FM. The effect of germ-line BRCA mutations
on response to chemotherapy and outcome of recurrent ovarian cancer.
International journal of gynecological cancer: official journal of the
international gynecological cancer. Society. 2014;24(3):488–95.
23. Adams SF, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, Sammel MD,
et al. A high response rate to liposomal doxorubicin is seen among women
with BRCA mutations treated for recurrent epithelial ovarian cancer.
Gynecol Oncol. 2011;123(3):486–91.
24. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al.
Germline and somatic mutations in homologous recombination genes
predict platinum response and survival in ovarian, fallopian tube, and
peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–75.
25. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;
474(7353):609–15.
26. Moller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, et al. Genetic
epidemiology of BRCA mutations–family history detects less than 50% of
the mutation carriers. European journal of cancer (Oxford, England: 1990).
2007;43(11):1713–7.
27. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, 2nd, et al.
Somatic mutations in BRCA1 and BRCA2 could expand the number of
patients that benefit from poly (ADP ribose) polymerase inhibitors in
ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol 2010;28(22):3570–3576.
28. Quach N, Goodman MF, Shibata D. Vitro mutation artifacts after formalin fixation
and error prone translesion synthesis during PCR. BMC Clin Pathol. 2004;4(1):1.
29. Hofreiter M, Jaenicke V, Serre D, von Haeseler A, Paabo SDNA. Sequences
from multiple amplifications reveal artifacts induced by cytosine
deamination in ancient DNA. Nucleic Acids Res. 2001;29(23):4793–9.
30. Chen G, Mosier S, Gocke CD, Lin MT, Eshleman JR. Cytosine deamination is
a major cause of baseline noise in next-generation sequencing. Mol Diagn
Ther. 2014;18(5):587–93.
31. Ng PC, Henikoff SSIFT. Predicting amino acid changes that affect protein
function. Nucleic Acids Res. 2003;31(13):3812–4.
32. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
et al. A method and server for predicting damaging missense mutations.
Nat Methods. 2010;7(4):248–9.
33. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, et al.
Performance comparison of benchtop high-throughput sequencing
platforms. Nat Biotechnol. 2012;30(5):434–9.
34. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al.
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
JAMA. 2000;283(17):2260–5.
35. Wilailak S, Linasmita VA. Study of pegylated liposomal doxorubicin in
platinum-refractory epithelial ovarian cancer. Oncology. 2004;67(3–4):183–6.
36. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical
characteristics of clear cell carcinoma of the ovary: a distinct histologic type
with poor prognosis and resistance to platinum-based chemotherapy.
Cancer. 2000;88(11):2584–9.
37. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL,
et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the
ovary or peritoneum. Gynecol Oncol. 2008;108(3):510–4.
38. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al. Mucinous
epithelial ovarian cancer: a separate entity requiring specific treatment.
J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(6):1040–4.
39. Douglas JA, Levin AM, Zuhlke KA, Ray AM, Johnson GR, Lange EM, et al.
Common variation in the BRCA1 gene and prostate cancer risk. Cancer
Epidemiol Biomarkers Prev. 2007;16(7):1510–6.
40. Merdad A, Gari MA, Hussein S, Al-Khayat S, Tashkandi H, Al-Maghrabi J, et al.
Characterization of familial breast cancer in Saudi Arabia. BMC genomics.
2015;16 Suppl 1:S3.
41. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, et al.
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations
with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393–402.
42. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G,
et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian
cancer. N Engl J Med. 2003;348(3):203–13.
43. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial
CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell
ratio are associated with favorable prognosis in ovarian cancer. Proc Natl
Acad Sci U S A. 2005;102(51):18538–43.
44. Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, et al.
The immunomodulatory effects of pegylated liposomal doxorubicin are
amplified in BRCA1–deficient ovarian tumors and can be exploited to improve
treatment response in a mouse model. Gynecol Oncol. 2014;133(3):584–90.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hollis et al. BMC Cancer  (2018) 18:16 Page 8 of 8
